Farydak® has been discontinued in the United States.

Please email projectfacilitate@securabio.com with any questions.

Secura Bio will make panobinostat available to certain multiple myeloma patients in the US who are currently receiving panobinostat.

To request access to panobinostat for multiple myeloma, a patient’s healthcare provider should contact Secura Bio to request access to panobinostat and submit a single patient IND request to FDA Oncology Center for Excellence’s Project Facilitate.

To request a single patient IND for panobinostat for a patient, Healthcare providers should access the Project Facilitate FDA website: https://www.fda.gov/about-fda/oncology-center-excellence/project-facilitate

Disclaimer: Secura Bio makes no guarantee that patients will qualify for access to panobinostat; and, if qualified, there may be limitations on the amount of drug available. Panobinostat remains available in the EU and UK.

© 2022 Secura Bio, Inc. All rights reserved.